UroToday - In the online version of Cancer, Dr. Marc Dall'Era and colleagues at UCSF report on their experience with active surveillance (AS) for prostate cancer (CaP). Active surveillance was offered to men with Gleason score 2ng/ml/year. Mean PSA doubling time was 6.7 years and 38% of the cohort had an increase in Gleason score on repeat biopsy.

The overall actuarial probabilities of not receiving treatment at 2 and 5 years were 85% and 67%, respectively. Men who had an increase in Gleason score on biopsy were 3.9 times as likely to convert to active treatment as men who had no increase.

Dall'era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR

Cancer. 2008 Apr 23 (Epub ahead of print)
doi:10.1002/cncr.23502

Reported by UroToday Contributing Editor Christopher P. Evans, MD, FACS

UroToday - the only urology website with original content global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday

Copyright © 2008 - UroToday